BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Abliva - ECPv6.15.19//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://abliva.com
X-WR-CALDESC:Events for Abliva
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Stockholm
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20241025
DTEND;VALUE=DATE:20241028
DTSTAMP:20260501T133625
CREATED:20240829T083852Z
LAST-MODIFIED:20241015T151503Z
UID:5387-1729814400-1730073599@abliva.com
SUMMARY:Mitocon's Mitochondrial Disease Conference
DESCRIPTION:In late October\, Abliva will attend the 14th Mitochondrial Disease Conference\, this year in Padua (IT)\, organized by the Italian patient organization Mitocon. \nAbliva’s CMO\, Magnus Hansson will attend the session: Roundtable with Pharmaceutical Industries and Regulatory Authorities. \nRead more by following the link below.
URL:https://abliva.com/event/mitocons-mitochondrial-disease-conference/
LOCATION:BW Plus Hotel Galileo\, Via Venezia 30\, Padova\, Italy
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2024/08/Padova_It.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240918
DTEND;VALUE=DATE:20240920
DTSTAMP:20260501T133625
CREATED:20240613T145109Z
LAST-MODIFIED:20240829T103736Z
UID:5306-1726617600-1726790399@abliva.com
SUMMARY:Nordic Life Science Days
DESCRIPTION:In September\, Abliva will attend the Nordic Life Science Days (NLS days) in Malmö\, Sweden. \nAblia’s CEO\, Ellen Donnelly\, will be presenting the company at 11:00 a.m. CET on September 18\, in the session Biotechnology. \nFollow the link below for more information.
URL:https://abliva.com/event/nordic-life-science-days-2/
LOCATION:Malmömässan\, Mässgatan 6\, Malmö\, 215 32\, Sweden
CATEGORIES:BD event,Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2021/10/malmo.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240626
DTEND;VALUE=DATE:20240630
DTSTAMP:20260501T133625
CREATED:20240402T134632Z
LAST-MODIFIED:20240402T134721Z
UID:5090-1719360000-1719705599@abliva.com
SUMMARY:Mito Med 2024
DESCRIPTION:In late June\, Abliva will attend the US patient organization UMDF’s Mitochondrial Medicine Conference in Cleveland\, Ohio. \n“Each year\, UMDF’s Mitochondrial Medicine Conference brings together the best minds in mitochondrial medicine and the patients we serve. With over 700 attendees representing almost every state in the U.S. and more than 15 different countries\, the Conference is recognized as the world’s preeminent event for mitochondrial disease.” \nClick the link below for more information.
URL:https://abliva.com/event/mito-med-2024/
LOCATION:Cleveland\, Ohio\, Cleveland\, OH\, United States
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2024/04/cleveland.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Stockholm:20240521T160000
DTEND;TZID=Europe/Stockholm:20240521T170000
DTSTAMP:20260501T133625
CREATED:20240502T152505Z
LAST-MODIFIED:20240502T152505Z
UID:5203-1716307200-1716310800@abliva.com
SUMMARY:Virtual KOL event on KL1333
DESCRIPTION:Join Abliva for a virtual KOL event featuring Amel Karaa\, MD (Massachusetts General Hospital)\, who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. \nThe event will focus on Abliva’s lead program\, KL1333\, which has shown clinically meaningful\, early signals of efficacy in mitochondrial disease patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333 is currently being evaluated in the pivotal Phase 2 FALCON trial\, with interim analysis expected mid-year 2024. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S. \nRegistration information \nRegister here: https://lifescievents.com/event/abliva/\nA live question and answer session will follow the formal presentation. Ask your question to: questions@lifesciadvisors.com. \nYou are required to register in advance for the webcast. For those who are unable to attend live\, a replay will be available via the link below.
URL:https://abliva.com/event/virtual-kol-event-on-kl1333/
CATEGORIES:Investor event,Scientific event
ATTACH;FMTTYPE=image/png:https://abliva.com/wp-content/uploads/2024/05/Abliva-Social-Media-v2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240318
DTEND;VALUE=DATE:20240321
DTSTAMP:20260501T133625
CREATED:20240122T100207Z
LAST-MODIFIED:20240318T085921Z
UID:4130-1710720000-1710979199@abliva.com
SUMMARY:Mitochondrial Medicine - Therapeutic Development
DESCRIPTION:In mid-March\, Abliva will attend the 8th edition of Mitochondrial Medicine – Therapeutic Development in Hinxton\, UK. \nThis annual scientific meeting is focused on mitochondrial disorders and the search for novel effective therapies. \nAbliva’s CMO\, Maguns Hansson\, will join the panel discussion Challenges and opportunities in clinical trials: perspectives\nfrom pharma and funders\, where representatives from other companies in the field as well as academic and clinical experts also participate. \nFollow the link below to learn more.
URL:https://abliva.com/event/mitochondrial-medicine-therapeutic-development-5/
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2024/01/Magnus_Fia_kameraa-e1710752165285.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230919
DTEND;VALUE=DATE:20230920
DTSTAMP:20260501T133625
CREATED:20230919T112132Z
LAST-MODIFIED:20230919T112132Z
UID:3881-1695081600-1695167999@abliva.com
SUMMARY:Empower & Inspire - 2nd Annual Leigh Syndrome Symposium
DESCRIPTION:During World Mitochondrial Disease Week\, Abliva’s Chief Medical Officer\, Magnus Hansson\, will present the company at the Cure Mito Foundation’s Empower & Inspire – 2nd Annual Leigh Syndrome Symposium (virtual). \nSee below for more information and the link to the event.
URL:https://abliva.com/event/empower-inspire-2nd-annual-leigh-syndrome-symposium/
LOCATION:Virtual
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2023/09/LS-symposium-presenting.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230907
DTEND;VALUE=DATE:20230908
DTSTAMP:20260501T133625
CREATED:20230621T120229Z
LAST-MODIFIED:20230621T120229Z
UID:3761-1694044800-1694131199@abliva.com
SUMMARY:The Future of Swedish & Danish Life Science
DESCRIPTION:Abliva will participate at the 12th annual edition of ‘The Future of Swedish & Danish Life Science’\, on September 7\, 2023\, in Lund\, Sweden. \nThe company’s Chief Medical Officer\, Magnus Hansson\, will give a talk entitled Pivotal study design in a rare disease with no regulatory precedent – utilizing patient advocacy groups and registries. \n“The Future of Swedish & Danish Life Science offers a dynamic full-day experience with highly relevant seminars\, networking and partnering meetings\, as well as a lively exhibition. The event annually draws around 500 influential decision-makers representing the pharma\, biotech and medtech sectors as well as academia\, healthcare\, policy makers\, regulatory authorities\, and financial services.” \nFollow the link below for more details.
URL:https://abliva.com/event/the-future-of-swedish-danish-life-science/
LOCATION:Restaurant Inspira\, Scheelevägen 4\, Lund\, 22363\, Sweden
CATEGORIES:BD event,Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2023/06/lunds_domkyrka.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230628
DTEND;VALUE=DATE:20230702
DTSTAMP:20260501T133625
CREATED:20230207T084239Z
LAST-MODIFIED:20230207T084239Z
UID:3549-1687910400-1688255999@abliva.com
SUMMARY:UMDF’s Mitochondrial Medicine Symposium 2023
DESCRIPTION:In late June\, Abliva will be attending this year’s international Mitochondrial Medicine Symposium\, organized by US patient organization United Mitochondrial Disease Foundation. \nThe meeting will take place in Charlotte\, North Carolina (US)\, on June 28 – July 1\, and includes both scientific as well as patient and family sessions.
URL:https://abliva.com/event/umdfs-mitochondrial-medicine-symposium-2023/
LOCATION:Sheraton Charlotte Hotel/Le Méridien\, 555 SOUTH MCDOWELL STREET\, Charlotte\, NC\, 28204\, United States
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2023/02/charlotte_NC_US.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20230611
DTEND;VALUE=DATE:20230616
DTSTAMP:20260501T133625
CREATED:20230116T103157Z
LAST-MODIFIED:20230116T103157Z
UID:3499-1686441600-1686873599@abliva.com
SUMMARY:Euromit 2023
DESCRIPTION:In June\, Abliva will attend this year’s edition of Euromit – the international conference on mitochondrial disease. \nThe meeting takes place in Bologna\, Italy\, and gathers researchers\, clinicians\, and patients for the sharing of knowledge and insights in the field. The conference also presents opportunities to meet with investigators in our FALCON study with KL1333.
URL:https://abliva.com/event/euromit-2023/
LOCATION:Bologna Congress Center\, Piazza della Costituzione\, 4/a\, Bologna\, Italy
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2023/01/bologna.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221121
DTEND;VALUE=DATE:20221124
DTSTAMP:20260501T133625
CREATED:20221114T101134Z
LAST-MODIFIED:20221122T084600Z
UID:3411-1668988800-1669247999@abliva.com
SUMMARY:Mitochondrial Medicine - Therapeutic Development
DESCRIPTION:In late November\, Abliva will attend the annual scientific conference Mitochondrial Medicine – Therapeutic Development in Hinxton\, UK. \nAbliva’s Chief Medical Officer\, Magnus Hansson\, will present a poster on one of the important preparatory studies for the upcoming\, potentially registrational\, Phase 2 study\, FALCON\, with KL1333 in patients with mitochondrial diseases.
URL:https://abliva.com/event/mitochondrial-medicine-therapeutic-development-3/
LOCATION:Wellcome Genome Campus\, Hinxton\, United Kingdom
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2020/10/Magnus_whiteboard.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221007
DTEND;VALUE=DATE:20221009
DTSTAMP:20260501T133625
CREATED:20220816T123412Z
LAST-MODIFIED:20221004T113151Z
UID:3313-1665100800-1665273599@abliva.com
SUMMARY:Mitocon's Mitochondrial Diseases Conference
DESCRIPTION:In October\, Abliva will attend the Italian patient organization Mitocon’s annual Mitochondrial Diseases Conference in Rome\, Italy. \nOn October 8\, Abliva’s Chief Medical Officer Magnus Hansson will give the talk: An adaptive\, clinical Phase 2/3 study evaluating the efficacy of KL1333 in adult primary mitochondrial disease patients in Session 5: Challenges and pitfalls in clinical trials design – presentations and round table discussion.
URL:https://abliva.com/event/mitocons-mitochondrial-diseases-conference/
LOCATION:Holiday Inn Rome EUR Parco dei Medici\, Rome\, Italy
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2022/08/Rome_Colosseo.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220915
DTEND;VALUE=DATE:20220918
DTSTAMP:20260501T133625
CREATED:20220815T141637Z
LAST-MODIFIED:20220815T141637Z
UID:3301-1663200000-1663459199@abliva.com
SUMMARY:mitoNice
DESCRIPTION:In September\, Abliva will attend mitoNice\, an international congress dedicated to Mitochondrial Medicine.
URL:https://abliva.com/event/mitonice/
LOCATION:Nice Acropolis Congress Center\, Nice\, France
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2022/08/Nice_France.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220629
DTEND;VALUE=DATE:20220701
DTSTAMP:20260501T133625
CREATED:20220621T123709Z
LAST-MODIFIED:20220621T123709Z
UID:3263-1656460800-1656633599@abliva.com
SUMMARY:Bioblast 2022: Inaugural Conference of Bioenergetics Communications
DESCRIPTION:On June 29-30\, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck\, Austria. \nAbliva’s Communications Officer & Lab Manager\, Eleonor Åsander Frostner\, will present a summary of the company’s recent preprint publication “Towards a treatment for mitochondrial disease: current compounds in clinical development“.
URL:https://abliva.com/event/bioblast-2022-inaugural-conference-of-bioenergetics-communications/
LOCATION:Congress Innsbruck\, Rennweg 3\, Innsbruck\, Austria
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2022/06/Innsbruck.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220608
DTEND;VALUE=DATE:20220612
DTSTAMP:20260501T133625
CREATED:20220608T114247Z
LAST-MODIFIED:20220608T114247Z
UID:3245-1654646400-1654991999@abliva.com
SUMMARY:UMDF's Mitochondrial Medicine Symposium
DESCRIPTION:Abliva will participate at the United Mitochondrial Disease Foundation’s Mitochondrial Medicine Symposium in Phoenix\, Arizona. \nAbliva’s CMO\, Magnus Hansson\, will participate in a panel discussion on clinical trials together with Baylor College of Medicine\, Cyclerion Therapeutics\, and Khondrion\, on Friday June 10.
URL:https://abliva.com/event/umdfs-mitochondrial-medicine-symposium/
LOCATION:JW Marriott Phoenix Desert Ridge Resort & Spa\, Phoenix\, AZ\, United States
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2022/06/Phoenix_Arizona.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220222
DTEND;VALUE=DATE:20220225
DTSTAMP:20260501T133625
CREATED:20211111T134348Z
LAST-MODIFIED:20211111T134348Z
UID:2973-1645488000-1645747199@abliva.com
SUMMARY:Mitochondria-Targeted Drug Development Summit
DESCRIPTION:Abliva will attend and present at the Mitochondria-Targeted Drug Development Summit in Boston\, MA\, USA. The event will be held on 22 – 24 February 2022. \nCEO Ellen Donnelly will be presenting in the session Patient-Focused Drug Development for Mitochondrial Disease. \nSynopsis: \n\nHighlighting the impact of patient input on research and development at Abliva\nProviding an overview of the multiple therapeutic options for mitochondrial disease being pursued at Abliva\nPresenting placebo controlled PMD patient data from our lead asset\, KL1333
URL:https://abliva.com/event/mitochondria-targeted-drug-development-summit/
LOCATION:Hyatt Regency Boston/Cambridge\, 575 Memorial Dr\, Cambridge\, Massachusetts\, 02139\, United States
CATEGORIES:Scientific event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211130
DTEND;VALUE=DATE:20211203
DTSTAMP:20260501T133625
CREATED:20211111T130531Z
LAST-MODIFIED:20211122T145635Z
UID:2970-1638230400-1638489599@abliva.com
SUMMARY:Mitochondrial Medicine - Therapeutic Development
DESCRIPTION:Abliva will attend the virtual conference Mitochondrial Medicine – Therapeutic Development\, organized by the Wellcome Connecting Science located at the Wellcome Genome Campus in the UK\, on 30 Nov – 2 Dec 2021. \nAbliva’s CMO\, Magnus Hansson\, has been invited to give a presentation on the topic Academia-pharma interplay in drug development\, during Session 1: Mitochondrial Medicine – pharma and funding perspectives.
URL:https://abliva.com/event/mitochondrial-medicine-therapeutic-development/
LOCATION:Virtual
CATEGORIES:Scientific event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211015
DTEND;VALUE=DATE:20211017
DTSTAMP:20260501T133625
CREATED:20211011T131302Z
LAST-MODIFIED:20211011T131302Z
UID:2916-1634256000-1634428799@abliva.com
SUMMARY:Mitochondrial Diseases Conference 2021
DESCRIPTION:Italian patient organization Mitocon arranges this year’s Mitochondrial Diseases Conference in virtual. \nAbliva’s Chief Medical Officer\, Magnus Hansson\, will give a flash presentation and join round table discussions at the meeting.
URL:https://abliva.com/event/mitochondrial-diseases-conference-2021/
LOCATION:Virtual
CATEGORIES:Scientific event
ATTACH;FMTTYPE=image/jpeg:https://abliva.com/wp-content/uploads/2021/10/Girls-heart_big.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210624
DTEND;VALUE=DATE:20210627
DTSTAMP:20260501T133625
CREATED:20210524T104537Z
LAST-MODIFIED:20210524T104758Z
UID:2775-1624492800-1624751999@abliva.com
SUMMARY:UMDF Mitochondrial Medicine
DESCRIPTION:The US patient organization United Mitochondrial Disease Foundation (UMDF) is hosting its annual Mitochondrial Medicine Symposium\, this year virtual\, in June. \nAbliva will participate in the scientific sessions: \n\nChief Medical Officer\, Magnus Hansson\, will constitute one of the panelists\, on Friday 25 June\, at 1:50 p.m. EST\, in the Clinical Trials Panel #2 Discussion\, together with representatives from Baylor College of Medicine\, Cyclerion Therapeutics\, and Khondrion.\nData from Abliva’s Phase 1a/b study with KL1333 will be presented on an e-Poster\, available to registered participants throughout the event.
URL:https://abliva.com/event/umdf-mitochondrial-medicine/
LOCATION:Virtual
CATEGORIES:Scientific event
END:VEVENT
END:VCALENDAR